{"text_format":"3","workbook":"xls","n_sheets":3,"sheets":["Sheet1","Sheet2","Sheet3"],"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"Sheet1","index":0,"n_rows":11,"n_cols":3,"rows_kept":11,"merged":[[1,0,2,0]],"flags":["formulas_cached_only"]}
["Supp Table 2. Objective Response in Patients With Wild-Type KRAS Exon 2 and Mutant Other RAS Exons"]
[null,"Panitumumab Plus BSC","BSC alone"]
[null,"(n=26)","(n=28)"]
["Objective response, n (%) "]
["Complete response","0 (0.0)","0 (0.0)"]
["Partial response","0 (0.0)","0 (0.0)"]
["Stable disease","11 (42.3)","6 (21.4)"]
["Disease progression","15 (57.7)","17 (60.7)"]
["Unevaluable/not done","0 (0.0)","5 (17.9)"]
["Objective response rate, % (95% CI)","0.0 (NE−NE)","0.0 (NE−NE)"]
["BSC, best supportive care; NE, not estimable."]

{"sheet":"Sheet2","index":1,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}

{"sheet":"Sheet3","index":2,"n_rows":0,"n_cols":0,"rows_kept":0,"flags":["formulas_cached_only"]}